Lipid Specialties Inc

Company Information

Company Name
Lipid Specialties Inc
Address
21 Tioga Way
Marblehead, MA, 01945
Phone
n/a
URL
n/a
DUNS
n/a
Number of Employees
4
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$317,000.00
7
Chart code to be here

Award List

  1. PERFLUOROCHEMICALS, DESPITE INSOLUBILITY IN WATER, HAVE SHOWN PROMISE AS OXYGEN CARRIERS IN ACELLULAR BLOOD SUBSTITUTES.

    Amount: $50,000.00

    PERFLUOROCHEMICALS, DESPITE INSOLUBILITY IN WATER, HAVE SHOWN PROMISE AS OXYGEN CARRIERS IN ACELLULAR BLOOD SUBSTITUTES. THE SURFACTANT USED FOR PERFLUOROCHEMICAL EMULSIONS IS MILDLY TOXIC, AND FLUOSO ...

    SBIR Phase I 1985 Department of Health and Human Services
  2. STUDIES IN THE MEDICAL LITERATURE SINCE THE 1970S HAVE STRONGLY SUGGESTED THAT EICOSAPENTAENOIC ACID (EPA) IS A SIGNIFICANT MODULATOR OF THROMBOXANE AND PROSTAGLANDIN ACTIVITY, PRIMARILY IN ITS ROLE AS A PRECURSOR OF THE 3 CLASS OF THROMBOXANES AND

    Amount: $33,000.00

    STUDIES IN THE MEDICAL LITERATURE SINCE THE 1970S HAVE STRONGLY SUGGESTED THAT EICOSAPENTAENOIC ACID (EPA) IS A SIGNIFICANT MODULATOR OF THROMBOXANE AND PROSTAGLANDIN ACTIVITY, PRIMARILY IN ITS ROLE A ...

    SBIR Phase I 1986 Department of Health and Human Services
  3. THE PRIMARY TREATMENT FOR GALLSTONES IS SURGICAL REMOVAL.

    Amount: $34,000.00

    THE PRIMARY TREATMENT FOR GALLSTONES IS SURGICAL REMOVAL. WITH A 1% MORTALITY RATE AND SUBSTANTIAL HOSPITALIZATION COSTS, A SEARCH FOR LESS EXPENSIVE AND SAFER TREATMENTS FOR GALLSTONE ELIMINATION IS ...

    SBIR Phase I 1986 Department of Health and Human Services
  4. THE PREPARATION OF PANCREATIC TISSUE EXTRACTS REQUIRES THE REMOVAL OF FATS-PRIMARILY TRIGLYCERIDES-FROM CRUDE TISSUE.

    Amount: $50,000.00

    THE PREPARATION OF PANCREATIC TISSUE EXTRACTS REQUIRES THE REMOVAL OF FATS-PRIMARILY TRIGLYCERIDES-FROM CRUDE TISSUE. SUCH EXTRACTED PANCREATIC TISSUE IS OF PARAMOUNT IMPORTANCE IN TREATING CYSTIC FIB ...

    SBIR Phase I 1986 Department of Health and Human Services
  5. NEW THERAPEUTIC AGENTS TO REDUCE TRIGLYCERIDE LEVELS

    Amount: $50,000.00

    HIGH TRIGLYCERIDE LEVELS HAVE BEEN SHOWN TO BE A RISK FACTOR IN CARDIOVASCULAR DISEASE. THE HIGH-DOSE DIETARY INTAKE OF MARINE OILS CONTAINING AN ESSENTIAL FATTY ACID, EICOSAPENTAENOIC ACID (EPA), HAS ...

    SBIR Phase I 1987 Department of Health and Human Services
  6. DEVELOPMENT OF NEW ANTI-PLATELET AGGREGATING AGENTS

    Amount: $50,000.00

    PLATELET AGGREGATION PLAYS A MAJOR ROLE IN CARDIOVASCULAR DISEASE. MUCH OF THE PRESENT PHARMACEUTICAL RESEARCH IS FOCUSED ON INHIBITORS OF THE FORMATION OF THROMBOXANE A2, A PROSTAGLANDIN DERIVED FROM ...

    SBIR Phase I 1987 Department of Health and Human Services
  7. IMPROVED INFANT NUTRITIONAL FORMULATIONS

    Amount: $50,000.00

    IT HAS BEEN SHOWN THAT LONG CHAIN POLYUNSATURATED ESSENTIAL FATTY ACIDS SUCH AS GAMMA LINOLENIC ACID (GLA), EICOSAPENTAENOIC ACID (EPA), AND DOCOSAHEXAENOIC ACID (DHA) ARE PRESENT IN VERY HIGH CONCENT ...

    SBIR Phase I 1988 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government